The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's (Q89334340)
Jump to navigation
Jump to search
scientific article published on 08 March 2018
Language | Label | Description | Also known as |
---|---|---|---|
English | The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's |
scientific article published on 08 March 2018 |
Statements
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort (English)
Pierre N Tariot
Francisco Lopera
Jessica B Langbaum
Ronald G Thomas
Suzanne Hendrix
Lon S Schneider
Silvia Rios-Romenets
Margarita Giraldo
Natalia Acosta
Carlos Tobon
Claudia Ramos
Alejandro Espinosa
William Cho
Michael Ward
David Clayton
Michael Friesenhahn
Howard Mackey
Lee Honigberg
Sandra Sanabria Bohorquez
Kewei Chen
Trisha Walsh
Carolyn Langlois
Eric M Reiman
Alzheimer's Prevention Initiative
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference